Publication Name	World Journal of Clinical Oncology
Manuscript ID	17519
Country	Italy

Received	2015-03-12 10:06
Peer-Review Started	2015-03-18 19:47
To Make the First Decision	2015-06-03 14:39
Return for Revision	2015-06-04 16:46
Revised	2015-06-15 18:46
Second Decision	2015-07-17 08:14
Accepted by Journal Editor-in-Chief	2015-07-18 01:45
Accepted by Executive Editor-in-Chief	2015-07-27 17:02
Articles in Press	2015-07-27 17:02
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2015-09-24 13:43
Publish the Manuscript Online	2015-10-13 10:26

ISSN	2218-4333 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Editorial
Article Title	Is there still a place for docetaxel rechallenge in prostate cancer?
Manuscript Source	Invited Manuscript
All Author List	Roberto Petrioli, Edoardo Francini and Giandomenico Roviello
Funding Agency and Grant Number
Corresponding Author	Roberto Petrioli, MD, Medical Oncology Unit, Department of Medicine, Surgery and Neurosciences, University of Siena, Viale Bracci 11, 53100 Siena, Italy. r.petrioli@ao-siena.toscana.it
Key Words	Abiraterone acetate; Docetaxel; Prostate cancer; Prostate-specific antigen; Rechallenge
Core Tip	New treatment options are currently available for metastatic castrate-resistant prostate cancer (mCRPC) patients after first-line chemotherapy with docetaxel. The actual role of docetaxel rechallenge in the evolving scenario of mCRPC treatment is discussed in this editorial.
Publish Date	2015-10-13 10:26
Citation	Petrioli R, Francini E, Roviello G. Is there still a place for docetaxel rechallenge in prostate cancer? World J Clin Oncol 2015; 6(5): 99-103
URL	http://www.wjgnet.com/2218-4333/full/v6/i5/99.htm
DOI	http://dx.doi.org/10.5306/wjco.v6.i5.99

Full Article (PDF)	WJCO-6-99.pdf
Full Article (Word)	WJCO-6-99.doc
Manuscript File	17519-Review.doc
Answering Reviewers	17519-Answering reviewers.pdf
Audio Core Tip	17519-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	17519-Conflict-of-interest statement.pdf
Copyright License Agreement	17519-Copyright assignment.pdf
Peer-review Report	17519-Peer-review(s).pdf
Journal Editor-in-Chief Review Report	17519-Journal editor-in-chief review report.pdf
Scientific Misconduct Check	17519-Scientific misconduct check.pdf
Scientific Editor Work List	17519-Scientific editor work list.pdf